Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ, Chiang CP
Journal
Experimental & molecular medicine
Year
2021
In Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that the gut microbiota plays a critical role in breast cancer. However, studies on the gut microbiota in the context of breast cancer have mainly focused on postmenopausal breast cancer. Little is known about the gut microbiota in the context of premenopausal breast cancer. This study aimed to comprehensively explore the gut microbial profiles, diagnostic value, and functional pathways in premenopausal breast cancer patients. Here, we analyzed 267 breast cancer patients with different menopausal statuses and age-matched female controls. The α-diversity was significantly reduced in premenopausal breast cancer patients, and the β-diversity differed significantly between breast cancer patients and controls. By performing multiple analyses and classification, 14 microbial markers were identified in the different menopausal statuses of breast cancer. Bacteroides fragilis was specifically found in young women of premenopausal statuses and Klebsiella pneumoniae in older women of postmenopausal statuses. In addition, menopausal-specific microbial markers could exhibit excellent discriminatory ability in distinguishing breast cancer patients from controls. Finally, the functional pathways differed between breast cancer patients and controls. Our findings provide the first evidence that the gut microbiota in premenopausal breast cancer patients differs from that in postmenopausal breast cancer patients and shed light on menopausal-specific microbial markers for diagnosis and investigation, ultimately providing a noninvasive approach for breast cancer detection and a novel strategy for preventing premenopausal breast cancer.
Experiment 1
Subjects
- Location of subjects
- Taiwan
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Breast carcinoma breast cancer,breast cancer, NOS,breast carcinoma,cancer of breast,cancer of the breast,cancer, breast,carcinoma of breast,carcinoma of the breast,mammary carcinoma,Breast carcinoma
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- premenopausal female controls (Pre-C)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- premenopausal breast cancer patients (Pre-BC)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with premenopausal breast cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 50
- Group 1 sample size Number of subjects in the case (exposed) group
- 100
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Within 4 weeks
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2.0
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
Signature 1
Source: FIG 2 (B)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Pre-C and Pre-BC.
Abundance in Group 1: increased abundance in premenopausal breast cancer patients (Pre-BC)
| NCBI | Quality Control | Links |
|---|---|---|
| Haemophilus | ||
| Fusobacterium | ||
| Sutterella | ||
| Bacteroides | ||
| Haemophilus parainfluenzae | ||
| Ruminococcus bromii | ||
| Ruminococcus callidus | ||
| Leyella stercorea |
Revision editor(s): Rahila
Signature 2
Source: FIG 2 (B)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Pre-C and Pre-BC.
Abundance in Group 1: decreased abundance in premenopausal breast cancer patients (Pre-BC)
Revision editor(s): Rahila
Experiment 2
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- postmenopausal female controls (Post-C)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- postmenopausal breast cancer patients (Post-BC)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with postmenopausal breast cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 17
Lab analysis
Statistical Analysis
Signature 1
Source: FIG 2 (C)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Post-C and Post-BC.
Abundance in Group 1: increased abundance in postmenopausal breast cancer patients (Post-BC)
| NCBI | Quality Control | Links |
|---|---|---|
| Actinomyces | ||
| Mitsuokella | ||
| Haemophilus | ||
| Sutterella | ||
| Mitsuokella multacida | ||
| Haemophilus parainfluenzae |
Revision editor(s): Rahila
Signature 2
Source: FIG 2 (C)
Description: Microbial markers at the genus/species levels between control individuals and breast cancer patients. The potential microbial markers between Post-C and Post-BC.
Abundance in Group 1: decreased abundance in postmenopausal breast cancer patients (Post-BC)
Revision editor(s): Rahila
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_915&oldid=129342"
Hidden category:
